MedTrace Logo

Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis

NCT05110937 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2026-08-19

No results posted yet for this study

Summary

Adverse outcomes in surgical sepsis patients are secondary to dysregulated emergency myelopoiesis, and expansion of myeloid-derived suppressor cells. Here we propose to determine the underlying mechanisms behind the increased expansion of these leukocyte populations and the underlying mechanisms that drive inflammation and immune suppression.

Conditions

Interventions

OTHER

Blood sampling

Blood sampling

Sponsors & Collaborators

  • National Institute of General Medical Sciences (NIGMS)

    collaborator NIH

  • University of Florida

    lead OTHER

Principal Investigators

  • Lyle Moldawer, PhD · University of Florida

  • Philip Efron, MD · University of Florida

  • Tyler Loftus, MD · University of Florida

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-04
Primary Completion
2028-07-01
Completion
2029-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05110937 on ClinicalTrials.gov